Skip Nav Destination
Issues
1 July 2021
-
Cover Image
Cover Image
Close-up view of the binding interface between PCA062 (light cyan/violet ribbon), a therapeutic antibody drug conjugate and its target protein antigen, human P-cadherin (gold ribbon), a cell surface glycoprotein highly expressed in several human malignancies. Glutamate E155, a central epitope residue, is unique to human P-cadherin, thus conferring this antibody exquisite selectivity in delivering its toxic payload to P-cadherin expressing cancer cells. Read the full manuscript by Sheng and colleagues on page 1270. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
ISSN 1535-7163
EISSN 1538-8514
Highlights
Review
Small Molecule Therapeutics
Combined Blockade of MEK and CDK4/6 Pathways Induces Senescence to Improve Survival in Pancreatic Ductal Adenocarcinoma
Brent A. Willobee; Alexander A. Gaidarski; Austin R. Dosch; Jason A. Castellanos; Xizi Dai; Siddharth Mehra; Fanuel Messaggio; Supriya Srinivasan; Michael N. VanSaun; Nagaraj S. Nagathihalli; Nipun B. Merchant
Author Choice
Combined Inhibition of Rad51 and Wee1 Enhances Cell Killing in HNSCC Through Induction of Apoptosis Associated With Excessive DNA Damage and Replication Stress
Antje Lindemann; Ameeta A. Patel; Lin Tang; Noriaki Tanaka; Frederico O. Gleber-Netto; Mason D. Bartels; Li Wang; Daniel J. McGrail; Shiaw-Yih Lin; Steven J. Frank; Mitchell J. Frederick; Jeffrey N. Myers; Abdullah A. Osman
Large Molecule Therapeutics
PCA062, a P-cadherin Targeting Antibody–Drug Conjugate, Displays Potent Antitumor Activity Against P-cadherin–expressing Malignancies
Qing Sheng; Joseph A. D'Alessio; Daniel L. Menezes; Christopher Karim; Yan Tang; Angela Tam; Suzanna Clark; Chi Ying; Anu Connor; Keith G. Mansfield; Jean-Michel Rondeau; Majid Ghoddusi; Felipe C. Geyer; Jane Gu; Margaret E. McLaughlin; Rick Newcombe; GiNell Elliot; William R. Tschantz; Sylvie Lehmann; Christie P. Fanton; Kathy Miller; Thomas Huber; Katherine G. Rendahl; Ursula Jeffry; Nancy K. Pryer; Emma Lees; Paul Kwon; Judith A. Abraham; Jason S. Damiano; Tinya J. Abrams
Targeting Drug Resistance
Companion Diagnostic, Pharmacogenomic, and Cancer Biomarkers
BRAFV600E Mutation in Cell-Free DNA, Rather than in Lesion Tissues, at Diagnosis Is An Independent Prognostic Factor in Children with Langerhans Cell Histiocytosis
Chan-Juan Wang; Lei Cui; Hong-Hao Ma; Dong Wang; Li Zhang; Hong-Yun Lian; Wei-Jing Li; Qing Zhang; Tian-You Wang; Zhi-Gang Li; Rui Zhang
Advertisement
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.
RSS Feeds